 鲜花( 0)  鸡蛋( 0)
|
楼主 |
发表于 2005-9-22 16:22
|
显示全部楼层
转自Edmonton Journal
原文如下6 k# L5 K/ r- v. _$ e
+ r7 j* \' s- o; J3 T( Z* S
Researcher wins prestigious award
& O5 Y8 b/ o( E. I( P3 c , @# E. r% c0 v, D% A5 w
2 Z7 w% s+ G7 i4 C( t" [8 y, ^
Edmonton Journal
! o6 K* `' `' d
, M1 J+ g. A" D5 k' A! I/ q6 ?8 e0 w6 x
Wednesday, September 21, 2005
# |7 L: h) G5 K. n
+ |2 F/ q" G, Q a% y$ r) A. H* L' ~
+ u" K/ Z2 J' ^2 c. z' gAn Edmonton researcher whose work led to a breakthrough in treating chronic hepatitis B has received an award worth $100,000.
$ e: D1 K: S0 x7 Y; L- c& } Q8 n+ T) J% D, a# @( |
Dr. Lorne Tyrrell, former dean of medicine at the University of Alberta, was honoured by the Ernest C. Manning Awards Foundation for his lifetime work in treating the disease.
! ?0 a- p! z% O- ]) c
7 s! Y' Z8 z" B3 ^% ]He and his research team spent years testing chemical compounds to find a way of stopping hepatitis B viruses, which infect the liver and can cause cirrhosis of the liver, liver cancer, liver failure and death.5 h/ N7 l9 @* `: f# `0 ]. e
& [4 f. L3 ~- \, }* s8 w4 ]He says when he started his research, funding was so tight that he tested chemical compounds on livers of ducks he raised on his parents’ farm west of Edmonton.; ~9 \6 N' |9 k$ p8 E/ G
' u0 E( \& p! h! U8 `7 z2 u: @# a8 `
The research led to creation of the drug lamivudine, which was approved for use in the United States and Canada in 1998 and is now licensed in more than 120 countries for treatment of chronic hepatitis B infection.
! C* ]0 u$ z* K: c
9 ~6 m9 q, G OBefore lamivudine, which is taken orally, the only treatment was taking injections of interferon, which is expensive and had serious side effects.
3 z3 p9 @ { C8 x, P: ?- R& b* Z( e3 q/ P" z
The World Health Organization estimates that more than 350-million people around the world suffer from chronic hepatitis B. |
|
狗仔卡
发表于 2005-9-21 22:53
提升卡
置顶卡
沉默卡
喧嚣卡
变色卡
显身卡
我这就去欣赏你的大作。 W1 \( D- v! p' a* l3 U I
